Medical Research for Our Troops Act

What happened: On June 11, 2025, Rep. Carson (D-IN) introduced HR3906, the 'Medical Research for Our Troops Act,' which would amend the Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4) to restore $1.181 billion to Defense Health Agency RDT&E. The bill is in the earliest legislative stage — referred to the House Committee on Appropriations. It has 48 cosponsors, all Democrats. The bill is not a standalone appropriation; it redirects funding within an existing appropriations bill. The money trail: This is a RESTORATION of funding that was cut in PL 119-4, not new money. The bill increases the DHA RDT&E line item from $40,395,072,000 to $41,576,684,000 — a $1.181B increase. Crucially, this remains an AUTHORIZATION within existing appropriations. The bill instructs the Secretary of Defense to implement CDMRP in a manner consistent with the FY2024 Consolidated Appropriations Act, specifying that funds support all research programs, peer-reviewed initiatives, and projects identified in the explanatory statement accompanying PL 118-47. This provides a concrete roadmap for where money flows: to specific peer-reviewed medical research programs already identified by Congress. Structural winners: Companies with existing DoD medical research contracts and capabilities aligned with CDMRP priorities — trauma care, infectious disease, surgical innovation, orthopedics, and neurological health — are positioned to compete for awards. The tickers listed (, $PFE, $MRK, $MDT, $SYK) have the scale and regulatory infrastructure to win these contracts. However, no companies are named in the legislation. CDMRP awards are competitive and peer-reviewed; the funding increase expands the pool but does not guarantee any specific company wins. The Executive Order on accelerating medical treatments for serious mental illness (April 18, 2026) is moderately relevant: it creates a favorable regulatory environment for psychedelic therapies, which could be a subset of CDMRP's neuroscience research portfolio. This is complementary but indirect — the EO does not fund research; it accelerates FDA pathways. Real market data: The healthcare stocks tracked here show a broad 30-day decline. JNJ is down 5.27% from $238.67 to $227.79. MRK is down 8.02% from $117.90 to $110.03. PFE is down 2.07% from $27.19 to $26.48. MDT is down 6.01% from $87.10 to $81.90. SYK is down 1.84% from $341.24 to $321.43. These declines are consistent with broader market headwinds (tariff concerns, drug pricing legislation) and have no connection to this early-stage bill. The bill's introduction in June 2025 generated no measurable price reaction because it was procedural. Timeline: The bill has been sitting in the House Appropriations Committee since June 11, 2025 — no hearings, no markups, no floor votes. With the 119th Congress in its second year and a divided government, the path to passage is narrow. The bill would need to pass the House, pass the Senate, and be signed by the President. Given that this restores funding cut in the current CR budget framework, it is likely to be a priority for Democrats but faces Republican opposition in the Appropriations Committee. Odds of passage in the current Congress are below 30%.